Creative Planning’s Alaunos Therapeutics TCRT Stock Holding History

Creative Planning’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-67	Closed	-$8K	–	2543
2021 Q1	$8K	Buy	+67	New	+$41.7K	﹤0.01%	2492

Other funds holding TCRT

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACM

Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return

Creative Planning's TCRT Position: Q1 2024 in Review

Creative Planning sold out of Alaunos Therapeutics (TCRT) in Q1 2024, closing a stake of 171 shares — an estimated $1.81K sold.

Creative Planning first reported a position in TCRT in Q4 2013 and held it in 37 quarters. The position peaked at $525K in Q2 2019. 45 funds tracked by Wall St. Rank hold TCRT as of Q1 2024.

Creative Planning reported no remaining Alaunos Therapeutics position as of Q1 2024 after selling out during the quarter.
Creative Planning sold 171 Alaunos Therapeutics shares in Q1 2024, an estimated $1.81K.
Creative Planning first reported a position in Alaunos Therapeutics in Q4 2013 and held it in 37 quarters.
Creative Planning's Alaunos Therapeutics position peaked at $525K in Q2 2019.
45 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2024.

Based on Creative Planning's 13F filing for Q1 2024, filed 13 May 2024.